早期宫颈癌前哨淋巴结定位:全国性前瞻性多中心SENTIREC试验
SENTIREC试验前瞻性纳入245例早期宫颈癌患者评估前哨淋巴结(SLN)定位。SLN检出率96.3%,双侧检出率82.0%,38例(15.5%)有淋巴结转移。肿瘤>20mm者SLN算法敏感性96.3%、阴性预测值98.7%,FDG-PET/CT敏感性仅14.8%。结论认为SLN定位对≤20mm肿瘤是合适分期方法,>20mm需完全遵循算法并建议补充盆腔淋巴结清扫。
要点
- SLN定位在早期宫颈癌中检出率96.3%,双侧检出率82.0%
- 肿瘤>20mm者SLN算法敏感性96.3%、NPV 98.7%
- FDG-PET/CT淋巴结分期敏感性低(14.8%),价值有限
核心结论
- SLN定位对≤20mm早期宫颈癌是合适的分期方法。
- 肿瘤>20mm时SLN定位敏感性高但需完全遵循SLN算法。
- 建议>20mm肿瘤补充盆腔淋巴结清扫直至肿瘤学安全性确立。
- FDG-PET/CT用于早期宫颈癌淋巴结分期价值似乎有限。
研究设计与样本
- 全国性前瞻性多中心研究(SENTIREC试验)。
- 2017年3月至2021年1月纳入245例早期宫颈癌女性接受SLN定位。
- 肿瘤>20mm者行补充盆腔淋巴结清扫并切除FDG-PET/CT阳性淋巴结。
- 评估SLN检出率、淋巴结疾病发生率、SLN敏感性与NPV,以及FDG-PET/CT的敏感性、特异性、NPV和PPV。
主要发现
- 245例中38例(15.5%)有淋巴结转移。
- SLN检出率96.3%(236/245),双侧检出率82.0%(201/245)。
- 103例肿瘤>20mm者中27例(26.2%)有淋巴结转移。
- 遵循算法时SLN敏感性96.3%(95%CI 81.0-99.9%),NPV 98.7%(95%CI 93.0-100%)。
- FDG-PET/CT敏感性14.8%(95%CI 4.2-33.7%),特异性85.5%(95%CI 75.6-92.5%),NPV 73.9%(95%CI 63.4-82.7%),PPV 26.7%(95%CI 7.8-55.1%)。
关键数值与推荐
- SLN检出率96.3%(236/245),双侧检出率82.0%(201/245)。
- 肿瘤>20mm者SLN算法敏感性96.3%(95%CI 81.0-99.9%),NPV 98.7%(95%CI 93.0-100%)。
- FDG-PET/CT敏感性14.8%(95%CI 4.2-33.7%),特异性85.5%(95%CI 75.6-92.5%),NPV 73.9%(95%CI 63.4-82.7%),PPV 26.7%(95%CI 7.8-55.1%)。
临床怎么用
- 对肿瘤≤20mm的早期宫颈癌可采用SLN定位进行分期。
- 肿瘤>20mm时应严格遵循SLN算法操作。
- 肿瘤>20mm目前建议补充盆腔淋巴结清扫。
- FDG-PET/CT不宜单独用于早期宫颈癌淋巴结分期。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Sentinel lymph node (SLN) mapping may replace staging radical pelvic lymphadenectomy in women with early-stage cervical cancer. In a national multicenter setting, we evaluated SLN mapping in women with early-stage cervical cancer and investigated the accuracy of SLN mapping and FDG-PET/CT in tumors >20 mm. METHODS: We prospectively included women with early-stage cervical cancer from March 2017-January 2021 to undergo SLN mapping. Women with tumors >20 mm underwent completion pelvic lymphadenectomy and removal of FDG-PET/CT positive nodes. We determined SLN detection rates, incidence of nodal disease, sensitivity and negative predictive value (NPV) of SLN mapping, and the sensitivity, specificity, NPV, and positive predictive value (PPV) of FDG-PET/CT. RESULTS: We included 245 women, and 38 (15.5%) had nodal metastasis. The SLN detection rate was 96.3% (236/245), with 82.0% (201/245) bilateral detection. In a stratified analysis of 103 women with tumors >20 mm, 27 (26.2%) had nodal metastases. The sensitivity of SLN mapping adhering to the algorithm was 96.3% (95% CI 81.0-99.9%) and the NPV 98.7% (95% CI 93.0-100%). For FDG-PET/CT imaging the sensitivity was 14.8% (95% CI 4.2-33.7%), the specificity 85.5% (95% CI 75.6-92.5%), the NPV 73.9% (95% CI 63.4-82.7%), and the PPV 26.7% (95% CI 7.8-55.1%). CONCLUSIONS: SLN mapping seems to be an adequate staging procedure in early-stage cervical cancer tumors ≤20 mm. In tumors >20 mm, SLN mapping is highly sensitive but demands full adherence to the SLN algorithm. We recommend completion pelvic lymphadenectomy in tumors >20 mm until the oncological safety is established. FDG-PET/CT for nodal staging of women with early-stage cervical cancer seems limited.
引用
- Sponholtz SE, Mogensen O, Hildebrandt MG, et al. Sentinel lymph node mapping in early-stage cervical cancer - A national prospective multicenter study (SENTIREC trial). Gynecol Oncol. 2021. PMID: 34226018. doi:10.1016/j.ygyno.2021.06.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。